Explanation and Review Opinion on the Public Disclosure of the List of Incentive Objects for the 2026 Restricted Stock Incentive Plan
Securities Code: 301033
Securities Abbreviation: Maipu Medical
Announcement Number: 2026-038
The Board of Directors and all members guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (hereinafter referred to as "the Company") held the 20th meeting of the 3rd Board of Directors on May 18, 2026, to review and approve the proposal regarding the "2026 Restricted Stock Incentive Plan (Draft)" and related proposals. For specific details, please refer to the announcement disclosed by the Company on May 19, 2026, on the Giant Tide Information Network (http://www.cninfo.com.cn).
According to the relevant provisions of the "Company Law of the People's Republic of China," "Securities Law of the People's Republic of China," "Administrative Measures for Equity Incentives of Listed Companies," "Listing Rules for the Shenzhen Stock Exchange Growth Enterprise Market," "Self-Regulatory Guidelines No. 1 for Growth Enterprise Market Listed Companies - Business Handling," and the Company's Articles of Association, the Company publicly disclosed the basic information such as the names and positions of the incentive objects for the 2026 Restricted Stock Incentive Plan (hereinafter referred to as "this Incentive Plan") internally. The Compensation and Assessment Committee of the Board reviewed the list of incentive objects based on the public disclosure situation, and the relevant information is as follows: